References
- Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v31–9.10.1093/annonc/mdv199
- https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf
- Van Zandwijk N, Cralke C, HendersonD Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.
- Zalcman G, Mazieres J, Margery J, Greillier L, Audigler-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomized, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.
- Zauderer MG. A new standard for malignant pleural mesothelioma. The Lancet. 2016;387:1352–4.10.1016/S0140-6736(15)01311-2
- Li T, Puhan MA, Vedula SS, Singh S, Dickersin K. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 2011;9:79–83.10.1186/1741-7015-9-79
- Higgins JPT, Welton NJ. Network meta-analysis: a norm for comparative effectiveness?. The Lancet. 2015;386:628–30.10.1016/S0140-6736(15)61478-7
- Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101:447–459.10.1198/016214505000001302
- Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313–24.10.1002/(ISSN)1097-0258
- Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Meth. 2012;3:80–97.10.1002/jrsm.1037
- Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1. Value Health. 2011;14:417–28.10.1016/j.jval.2011.04.002
- Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897–900.10.1136/bmj.331.7521.897
- Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159:130–7.10.7326/0003-4819-159-2-201307160-00008
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.10.1200/JCO.2003.11.136
- van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment, of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–9.10.1200/JCO.20005.14.589
- Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy. 2006;26(5):641–54.10.1592/phco.26.5.641
- https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdf
- Van Cutsem E, Cunningham D, Maroun J, Carvantes A, Gimelius B. Raltitrexed: current clinical status and future directions. Annals of Oncology. 2002;13(4):513–22.10.1093/annonc/mdf054
- Rose MG, Farrel MP, Schitz JC. Thymidilate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer. 2002;1(4):290–9.
- https://www.cancer.gov/about-cancer/treatment/drugs/fda-bevacizumab
- https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf
- Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the Introduction of biosimilars. Semin Oncol. 2014;41(3 Suppl):S13–20.10.1053/j.seminoncol.2014.03.009
- Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmacoeconomics – an aid to better decision-making. J Eur Acad Dermatol Venereol. 2005;19(s1):34–9.10.1111/jdv.2005.19.issue-s1
- Woods B, Paracha N, Scott DA, Thatcher N. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer. 2012;75:261–7.10.1016/j.lungcan.2011.07.011